Potential of coconut oil and medium chain triglycerides in the prevention and treatment of Alzheimer’s disease

Publication date: Available online 15 January 2020Source: Mechanisms of Ageing and DevelopmentAuthor(s): Pratishtha Chatterjee, Malika Fernando, Binosha Fenando, Cintia B Dias, Tejal Shah, Renuka Silva, Shehan Williams, Steve Pedrini, Heidi Hillebrandt, Kathryn Goozee, Edward Barin, Hamid R Sohrabi, Manohar Garg, Stephen Cunnane, Ralph N MartinsAbstractAlzheimer’s disease (AD) is the most common form of dementia. Currently, there is no effective medication for the prevention or treatment of AD. This has led to the search for alternative therapeutic strategies. Coconut oil(CO) has a unique fatty acid composition that is rich in medium chain fatty acids(MCFA), a major portion of which directly reaches the liver via the portal vein, thereby bypassing the lymphatic system. Given that brain glucose hypometabolism is a major early hallmark of AD, detectable well before the onset of symptoms, ketone bodies from MCFA metabolism can potentially serve as an alternative energy source to compensate for lack of glucose utilisation in the brain. Additionally, neuroprotective antioxidant properties of CO have been attributed to its polyphenolic content. This review discusses how the metabolism of CO and MCFA may aid in compensating the glucose hypometabolism observed in the AD brain. Furthermore, we present the current evidence of the neuroprotective properties of CO on cognition, amyloid-β pathogenicity, inflammation and oxidative stress. The current review addresses the influen...
Source: Mechanisms of Ageing and Development - Category: Geriatrics Source Type: research

Related Links:

DEMENTIA is a cluster of symptoms associated with brain damage but its impact on the body does not stop there. A lesser known affected area is the bladder - here are three warning signs.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Condition:   Agitation in Patients With Dementia of the Alzheimer's Type Interventions:   Drug: AVP-786;   Drug: Placebo Sponsor:   Avanir Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Frontotemporal Dementia Intervention:   Biological: PR006 Sponsor:   Prevail Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Dementia;   Sleep Disorder;   Mild Cognitive Impairment;   Phototherapy Interventions:   Device: Green LED light;   Device: Red LED light (placebo) Sponsor:   Kaohsiung Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Agitation in Patients With Dementia of the Alzheimer's Type Interventions:   Drug: AVP-786;   Drug: Placebo Sponsor:   Avanir Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Frontotemporal Dementia Intervention:   Biological: PR006 Sponsor:   Prevail Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The antidepressant bupropion was no better than placebo in reducing apathy in nondepressed patients with Alzheimer-type dementia in a randomized controlled trial.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Psychiatry News Source Type: news
Safeguarding adults with dementia is an important part of everyday work for providers of adult social care. This quick guide aims to support care providers and staff to safeguard people with dementia during the crisis. There are increased concerns that, during the COVID-19 crisis, people may be more vulnerable to abuse or neglect.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
The intent of this trans-NIH initiative would be to invite research to determine the role and impact of digital health interventions (e.g., mobile health (mHealth), telemedicine and telehealth, health information technology, wearable devices) to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and other vulnerable populations (e.g., essential medical personnel, emergency responders, and frontline workers in essential businesses or services; people who are residents of chronic care facilities, co...
Source: National Institute of Mental Health - Category: Psychiatry Authors: Source Type: news
Notice NOT-AG-20-026 from the NIH Guide for Grants and Contracts
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
More News: Antidoxidants | Brain | Coconut Oil | Coconuts | Dementia | Geriatrics | Liver | Neurology | Urology & Nephrology